Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 310

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Open access
Sanders, Gillian D., Taira, Al V.·2003·Emerging Infectious Diseases
DOI 10.3201/eid0901.020168
Open this paper in CoChat — free account

Abstract

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor for cervical cancer. Given the substantial disease and death associated with HPV and cervical cancer, development of a prophylactic HPV vaccine is a public health priority. We evaluated the cost-effectiveness of vaccinating adolescent girls for high-risk HPV infections relative to current practice. A vaccine with a 75% probability of immunity against high-risk HPV infection resulted in a life-expectancy gain of 2.8 days or 4.0 quality-adjusted life days at a cost of $246 relative to current practice (incremental cost effectiveness of $22,755/quality-adjusted life year [QALY]). If all 12-year-old girls currently living in the United States were vaccinated, >1,300 deaths from cervical cancer would be averted during their lifetimes. Vaccination of girls against high-risk HPV is relatively cost effective even when vaccine efficacy is low. If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3201/eid0901.020168

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 310

Metadata

Authors
Sanders, G. D., & Taira, A. V.
Venue
Emerging Infectious Diseases
Publisher
Centers for Disease Control and Prevention (CDC)
Published
2003-01
Volume
9
Issue
1
Pages
37-48
ISSN
  • 1080-6040 (ISSN-L)
  • 1080-6059
DOI
10.3201/eid0901.020168
OpenAlex
W1969228545
Cited by
310
References
69
FWCI
12.56
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost Effectiveness of a Potential Vaccine for Human papillomavirus. https://app.cochat.ai/papers/10.3201/eid0901.020168
The paper
Sanders, G. D., & Taira, A. V. (2003). Cost Effectiveness of a Potential Vaccine for Human papillomavirus. Emerging Infectious Diseases. https://doi.org/10.3201/eid0901.020168

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.